 Abstract silicosis is a serious and life-threatening lung condition caused by prolonged exposure to crystalline silica dust. It can be treated with a drug called Nintedinib, but it must be taken orally in large doses which can cause unpleasant side effects. Researchers have now developed a new formulation of Nintedinib, called NTBNS, which can be administered through the lungs instead of the mouth. This formulation is made up of tiny particles of Nintedinib suspended in a liquid solution, allowing them to stay in the lungs longer and deliver more effective treatment. In tests, NTBNS was able to reduce the damage caused by silicosis and restore lung function while causing no noticeable side effects. This new formulation could provide a safe and effective way to treat silicosis and other similar conditions. This article was authored by Luisa Helena Andrade de Silva, Juliana Borges Vieira, Mariana Ribeiro Cabral, and others.